Literature DB >> 925191

Plasma levels and bioavailability of cyclobenzaprine in human subjects.

H B Hucker, S C Stauffer, K S Albert, B W Lei.   

Abstract

Cyclobenzaprine was extensively metabolized in man, less than 1% of the dose being excreted unchanged in the urine. Comparison of areas under plasma level curves (AUC) after oral and intravenous doses suggests that the drug may be partly metabolized in the lumen or during its first passage through the gut wall and/or liver. Average plasma levels of the drug increased with increasing dosage, but the AUC increased less rapidly with increasing dose, possibly because of dose-dependent absorption.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 925191     DOI: 10.1002/j.1552-4604.1977.tb01547.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  2 in total

1.  Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults : a randomized, open-label, two-period crossover, single-centre study.

Authors:  Mona Darwish; Edward T Hellriegel; Fang Xie
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

2.  Pharmacokinetics and bioequivalence evaluation of cyclobenzaprine tablets.

Authors:  Tatiane Maria de Lima Souza Brioschi; Simone Grigoleto Schramm; Eunice Kazue Kano; Eunice Emiko Mori Koono; Ting Hui Ching; Cristina Helena Dos Reis Serra; Valentina Porta
Journal:  Biomed Res Int       Date:  2013-09-16       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.